Auswahl klinischer und diagnostischer Ergebnisse bei entzündlichen Gelenkerkrankungen

Zusammenfassung

Zahlreiche Fortschritte in der Grundlagenforschung, in der Diagnostik und Therapie in den letzten Jahren führen dazu, dass Patienten mit einer entzündlichen Gelenkerkrankung eine Remission bzw. niedrigstmögliche Krankheitsaktivität, Lebensqualität, einen Erhalt ihrer Arbeitsfähigkeit als auch das Beibehalten der sozialen Integration beibehalten. Diese Erfolge werden schrittweise versucht, auf andere Autoimmunerkrankungen zu übertragen. Es zeigt sich gerade auf dem Gebiet der Medikamentenentwicklung jedoch immer wieder, dass es sich um pathogenetisch unterschiedlich verursachte Erkrankungen handelt und Therapieerfolge nicht immer gleichermaßen erreichbar sind. Jedoch sind inzwischen zahlreiche Medikamente zur Behandlung der entzündlichen Gelenkerkrankungen verfügbar, weitere werden derzeit intensiv in klinischen Studien geprüft bzw. sind zur Zulassungsentscheidung bei den Aufsichtsbehörden registriert. So sind auch in den nächsten Jahren weitere Therapiemöglichkeiten zu erwarten. Die rheumatoide Arthritis ist ein Beispiel dieser Erfolgsgeschichte, so dass inzwischen sogar die Frage diskutiert wird, ob diese Erkrankung präventiv zu behandeln und somit die Manifestation der Erkrankung zu stoppen ist. Diese Übersicht vermittelt eine Auswahl aktueller Forschungsergebnisse und Medikamentenentwicklungen bei entzündlichen Gelenkerkrankungen.

Abstract

Numerous advances in basic medical and biological research, diagnostics and therapy in recent years have resulted in patients with inflammatory joint disease achieving remission or the lowest possible disease activity, and maintaining quality of life, ability to work and social integration. These successes are being tried to transfer to other autoimmune diseases in a step-by-step approach. In the field of drug development, however, it has been shown repeatedly that these diseases have different pathogenetic causes, and that it is not possible to achieve equal treatment success in all cases. However, a large number of drugs are now available for the treatment of inflammatory joint diseases; others are being studied intensively in clinical trials or are registered with the regulatory authorities. Further therapeutic possibilities are to be expected in the coming years. Rheumatoid arthritis is an example of this success story, so there are discussions ongoing on whether or not it would be possible to treat this disease preventively, thereby stopping its manifestation in the first place. This overview provides a selection of current research results and drug developments in inflammatory joint diseases.

Schlüsselwörter

Rheumatoide Arthritis - Psoriasisarthritis - Spondyloarthritis - Biologika - DMARD, JAK

Key words

Rheumatoid Arthritis - Psoriasis arthritis - Spondyloarthritis - Biologics - DMARD - JAK

• Literatur

• 1 Combe B, Landewe R, Daien CI. et al. 2016; update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis 2017; 76: 948-959
• 2 van der Heijde D, Ramiro S, Landewé R. et al. 2016; update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017; 76: 978-991
• 3 Smolen JS, Landewe R, Bijlsma J. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017; 76: 960-977
• 4 Daien CI, Hua C, Combe B. et al. Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis. RMD Open 2017; 3: e000404
• 5 Hua C, Daien CI, Combe B. et al. Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis. RMD Open 2017; 3: e000406
• 6 Pisetsky DS. EULAR recommendations for disease management: guidance not guidelines. Ann Rheum Dis 2017; 76: 935-938
• 7 Agca R, Heslinga SC, Rollefstad S. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017; 76: 17-28
• 8 Turina MC, Yeremenko N, van Gaalen F. et al. Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort. RMD Open 2017; 3: e000319
• 9 Christiansen AA, Hendricks O, Kuettel D. et al. Limited Reliability of Radiographic Assessment of Sacroiliac Joints in Patients with Suspected Early Spondyloarthritis. J Rheumatol 2017; 44: 70-77
• 10 Cárdenas M, de La Fuente S, Castro-Villegas MC. et al Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry. Rheumatol Int 2016; 36: 1627-1632
• 11 Choi M, Hyun MK, Choi S. et al. Comparative efficacy of biological agents in methotrexate-refractory rheumatoid arthritis patients: a Bayesian mixed treatment comparison. Korean J Intern Med 2017; 32: 536-547
• 12 Degli Esposti L, Favalli EG, Sangiorgi D. et al. Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy. Clinicoecon Outcomes Res 2017; 9: 9-17
• 13 Stevenson MD, Wailoo AJ, Tosh JC. et al. The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate. J Rheumatol DOI: 10.3899/jrheum.160941.
• 14 Verschueren P, de Cock D, Corluy L. et al Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-l\textellipsis. Ann Rheum Dis 2017; 76: 511-520
• 15 Bansback N, Phibbs CS, Sun H. et al. Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. Ann Intern Med DOI: 10.7326/M16-0713.
• 16 Behrens EM, Koretzky GA. Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era. Arthritis Rheumatol 2017; 69: 1135-1143
• 17 Jansen JP, Incerti D, Mutebi A. et al. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. J Med Econ 2017; 1-12
• 18 Schneider M. Neue Optionen für die Praxis: „Update S1/S2-Leitlinie Rheumatoide Arthritis“?. Z Rheumatol 2017; 76: 125-132
• 19 Weber S, Pongratz G, Schneider M. et al. Notwendigkeit für Verbesserungen der berichteten Kosten-Nutzen-Bewertung von Adalimumab bei Rheumatoider Arthritis in Deutschland. Z Rheumatol 2017; 76: 183-184
• 20 Gorwood P, Pouchot J, Vinceneux P. et al. Rheumatoid arthritis and schizophrenia: a negative association at a dimensional level. Schizophr Res 2004; 66: 21-29
• 21 Sellgren C, Frisell T, Lichtenstein P. et al. The association between schizophrenia and rheumatoid arthritis: a nationwide population-based Swedish study on intraindividual and familial risks. Schizophr Bull 2014; 40: 1552-1559
• 22 Ohi K, Kikuchi M, Ikeda M. et al. Polygenetic components for schizophrenia, bipolar disorder and rheumatoid arthritis predict risk of schizophrenia. Schizophr Res 2016; 175: 226-229
• 23 Malavia TA, Chaparala S, Wood J. et al. Generating testable hypotheses for schizophrenia and rheumatoid arthritis pathogenesis by integrating epidemiological, genomic, and protein interaction data. NPJ Schizophr 2017; 3: 11
• 24 Meng W, Zhu Z, Jiang X. et al. DNA methylation mediates genotype and smoking interaction in the development of anti-citrullinated peptide antibody-positive rheumatoid arthritis. Arthritis Res Ther 2017; 19: 71
• 25 Rykova E, Sizikov A, Roggenbuck D. et al. Circulating DNA in rheumatoid arthritis: pathological changes and association with clinically used serological markers. Arthritis Res Ther 2017; 19: 85
• 26 Manivel VA, Mullazehi M, Padyukov L. et al. Anticollagen type II antibodies are associated with an acute onset rheumatoid arthritis phenotype and prognosticate lower degree of inflammation during 5 years follow-up. Ann Rheum Dis DOI: 10.1136/annrheumdis-2016-210873.
• 27 Catapano AL, Pirillo A, Norata GD. Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. Br J Pharmacol DOI: 10.1111/bph.13805.
• 28 McInnes IB, Thompson L, Giles JT. et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis 2015; 74: 694-702
• 29 Garcia-Gomez C, Martin-Martinez MA, Castaneda S. et al. Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project. J Clin Lipidol 2017; 11: 749-756.e3
• 30 Bender P, Burgin WB, Sculean A. et al. Serum antibody levels against Porphyromonas gingivalis in patients with and without rheumatoid arthritis - a systematic review and meta-analysis. Clin Oral Investig 2017; 21: 33-42
• 31 Bae S, Lee YH. Association between anti-Porphyromonas gingivalis antibody, anti-citrullinated protein antibodies, and rheumatoid arthritis: A meta-analysis. Z Rheumatol DOI: 10.1007/s00393-017-0328-y.
• 32 Forslind K, Svensson B. MRI evidence of persistent joint inflammation and progressive joint damage despite clinical remission during treatment of early rheumatoid arthritis. Scand J Rheumatol 2016; 45: 99-102
• 33 Ramirez J, Narvaez JA, Ruiz-Esquide V. et al. Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up. Semin Arthritis Rheum DOI: 10.1016/j.semarthrit.2017.04.007.
• 34 Kawashiri S, Fujikawa K, Nishino A. et al. Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled. Arthritis Res Ther 2017; 19: 108
• 35 van Gestel AM, Prevoo ML, van 't Hof MA. et al Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 34-40
• 36 Smolen JS, Aletaha D. Monitoring rheumatoid arthritis. Curr Opin Rheumatol 2011; 23: 252-258
• 37 Ostergaard M, Peterfy C, Conaghan P. et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 2003; 30: 1385-1386
• 38 Sewerin P, Vordenbaeumen S, Hoyer A. et al. Silent progression in patients with rheumatoid arthritis: is DAS28 remission an insufficient goal in RA? Results from the German Remission-plus cohort. BMC Musculoskelet Disord 2017; 18: 163
• 39 Safy M, Jacobs JW, IJff ND. et al. Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial. Ann Rheum Dis DOI: 10.1136/annrheumdis-2016-210647.
• 40 van Vollenhoven RF, Chatzidionysiou K. Rheumatoid arthritis. Triple therapy or etanercept after methotrexate failure in RA?. Nat Rev Rheumatol 2013; 9: 510-512
• 41 O'Dell JR, Mikuls TR, Taylor TH. et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013; 369: 307-318
• 42 Meyfroidt S, van Hulst L, de Cock D. et al Factors influencing the prescription of intensive combination treatment strategies for early rheumatoid arthritis. Scand J Rheumatol 2014; 43: 265-272
• 43 Aletaha D, Bingham CO, Tanaka Y. et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet 2017; 389: 1206-1217
• 44 Raimondo MG, Biggioggero M, Crotti C. et al. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Devel Ther 2017; 11: 1593-1603
• 45 Burmester GR, McInnes IB, Kremer J. et al. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Ann Rheum Dis 2017; 76: 1020-1030
• 46 Park JK, Lee MA, Lee EY. et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis DOI: 10.1136/annrheumdis-2017-211128.
• 47 Katz P, Margaretten M, Gregorich S et al. Physical Activity to Reduce Fatigue in Rheumatoid Arthritis: A Randomized, Controlled Trial. Arthritis Care Res (Hoboken) 2017 n/a-n/a
• 48 Bowness P. HLA-B27. Annu Rev Immunol 2015; 33: 29-48
• 49 Lin H, Gong Y. Association of HLA-B27 with ankylosing spondylitis and clinical features of the HLA-B27-associated ankylosing spondylitis: a meta-analysis. Rheumatol Int DOI: 10.1007/s00296-017-3741-2.
• 50 Haroon NN, Paterson JM, Li P. et al. Patients With Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality: A Population-Based Study. Ann Intern Med 2015; 163: 409-416
• 51 Chou C, Lin M, Peng C. et al. A nationwide population-based retrospective cohort study: increased risk of acute coronary syndrome in patients with ankylosing spondylitis. Scand J Rheumatol 2014; 43: 132-136
• 52 Eriksson JK, Jacobsson L, Bengtsson K. et al. Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis?. Ann Rheum Dis 2017; 76: 364-370
• 53 Essers I, Stolwijk C, Boonen A. et al. Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. Ann Rheum Dis 2016; 75: 203-209
• 54 Brophy S, Cooksey R, Atkinson M. et al. No increased rate of acute myocardial infarction or stroke among patients with ankylosing spondylitis-a retrospective cohort study using routine data. Semin Arthritis Rheum 2012; 42: 140-145
• 55 Han C, Robinson JR DW, Hackett MV. et al Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006; 33: 2167-2172
• 56 Keller JJ, Hsu J, Lin S. et al. Increased risk of stroke among patients with ankylosing spondylitis: a population-based matched-cohort study. Rheumatol Int 2014; 34: 255-263
• 57 Szabo SM, Levy AR, Rao SR. et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum 2011; 63: 3294-3304
• 58 Bengtsson K, Forsblad-d'Elia H, Lie E. et al. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res Ther 2017; 19: 102
• 59 Oza A, Lu N, Choi H. Survival Benefit of Statin Use in Ankylosing Spondylitis and Psoriatic Arthritis: A General Population-Based Cohort Study [abstract]. In: Arthritis Rheumatol (Suppl 10): abstract-no.: 910
• 60 Xia Q, Fan D, Yang X. et al. Progression rate of ankylosing spondylitis in patients with undifferentiated spondyloarthritis: A systematic review and meta-analysis. Medicine (Baltimore) 2017; 96: e5960
• 61 Hellgren K, Dreyer L, Arkema EV. et al. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. Ann Rheum Dis 2017; 76: 105-111
• 62 Toussirot E. New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents. Expert Opin Pharmacother 2017; 18: 275-282
• 63 Sepriano A, Regel A, van der Heijde D. et al. Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open 2017; 3: e000396
• 64 Marzo-Ortega H, Sieper J, Kivitz A. et al. Secukinumab sustains improvement in signs and symptoms of patients with active ankylosing spondylitis through 2 years: Results from a phase 3 study. Arthritis Care Res (Hoboken) DOI: 10.1002/acr.23233.
• 65 Sieper J, Deodhar A, Marzo-Ortega H. et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis 2017; 76: 571-592
• 66 Baraliakos X, Kivitz AJ, Deodhar AA et al. Long-term effects of interleukin-17 A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clin Exp Rheumatol 2017
• 67 Villani AP, Rouzaud M, Sevrain M. et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. J Am Acad Dermatol 2015; 73: 242-248
• 68 Cretu D, Gao L, Liang K. et al. Novel serum biomarkers differentiate psoriatic arthritis from psoriasis without psoriatic arthritis. Arthritis Care Res (Hoboken) DOI: 10.1002/acr.23298.
• 69 Raychaudhuri SP, Wilken R, Sukhov AC. et al. Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies. J Autoimmun 2017; 76: 21-37
• 70 Mishra S, Kancharla H, Dogra S. et al. Comparison of four validated psoriatic arthritis screening tools in diagnosing psoriatic arthritis in patients with psoriasis (COMPAQ Study). Br J Dermatol 2017; 176: 765-770
• 71 Eder L, Polachek A, Rosen CF. et al. The Development of Psoriatic Arthritis in Patients With Psoriasis Is Preceded by a Period of Nonspecific Musculoskeletal Symptoms: A Prospective Cohort Study. Arthritis Rheumatol 2017; 69: 622-629
• 72 Taylor W, Gladman D, Helliwell P. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-2673
• 73 Deane KD, El-Gabalawy H. Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. Nat Rev Rheumatol 2014; 10: 212-228
• 74 Deane KD, Striebich CC, Holers VM. Editorial: Prevention of Rheumatoid Arthritis: Now Is the Time, but How to Proceed?. Arthritis Rheumatol 2017; 69: 873-877
• 75 Megna M, Gisonni P, Napolitano M. et al. The effect of smartphone addiction on hand joints in psoriatic patients: an ultrasound-based study. J Eur Acad Dermatol Venereol DOI: 10.1111/jdv.14380.
• 76 Ogdie A, Harter L, Shin D. et al. The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study. Ann Rheum Dis DOI: 10.1136/annrheumdis-2016-210441.
• 77 Cantini F, Niccoli L, Nannini C. et al. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum DOI: 10.1016/j.semarthrit.2017.03.008.
• 78 Gossec L, Coates LC, de Wit M. et al Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol 2016; 12: 743-750
• 79 Lemos LLP, de Oliveira Costa J, Almeida AM. et al Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety. Rheumatol Int 2014; 34: 1345-1360
• 80 Fenix-Caballero S, Alegre-del Rey EJ, Castano-Lara R. et al. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. J Clin Pharm Ther 2013; 38: 286-293
• 81 Acosta Felquer ML, Coates LC, Soriano ER. et al. Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review. J Rheumatol 2014; 41: 2277-2285
• 82 McInnes IB, Mease PJ, Kirkham B. et al. Secukinumab, a human anti-interleukin-17 A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2015; 386: 1137-1146
• 83 Rose S, Toloza S, Bautista-Molano W. et al Comprehensive Treatment of Dactylitis in Psoriatic Arthritis. J Rheumatol 2014; 41: 2295-2300
• 84 Orbai A, Weitz J, Siegel EL. et al. Systematic Review of Treatment Effectiveness and Outcome Measures for Enthesitis in Psoriatic Arthritis. J Rheumatol 2014; 41: 2290-2294
• 85 Blauvelt A, Reich K, Mehlis S. et al. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study. J Eur Acad Dermatol Venereol DOI: 10.1111/jdv.14391.
• 86 U.S. FDA. FDA approves new psoriasis drug 2017;
• 87 Farahnik B, Beroukhim K, Abrouk M. et al. Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials. Dermatol Ther (Heidelb) 2016; 6: 111-124
• 88 Nash P, Kirkham B, Okada M. et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. The Lancet DOI: 10.1016/S0140-6736: 31429-0.
• 89 Reich K, Armstrong AW, Foley P. et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 2017; 76: 418-431
• 90 Blauvelt A, Papp KA, Griffiths CEM. et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017; 76: 405-417
• 91 Smolen JS, Agarwal SK, Ilivanova E. et al. A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Ann Rheum Dis 2017; 76: 831-839
• 92 Snast I, Atzmony L, Braun M. et al. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. J Am Acad Dermatol DOI: 10.1016/j.jaad.2017.01.037.
• 93 Riechers E, Baerlecken N, Baraliakos X. et al Studienergebnisse der Inter-SpA: Sensitivität und Spezifität von IgA-anti-CD74 bei früher axialer Spondyloarthritis (axSpA). DGRh 2016; DOI: 10.3205/16dgrh024, urn:nbn:de:0183-16dgrh0247.
• 94 Matthias T, Schweikard E, Reuter S. et al. Autoantibodies Against CD74 – a New Diagnostic Marker for Spondyloarthritis (SpA). DGRh 2016; DOI: 10.3205/16dgrh103. urn:nbn:de:0183-16dgrh1036
• 95 Matthias T, Schweikard E, Reuter S et al. Autoantibodies Against CD74 – a New Diagnostic Marker for Spondyloarthritis (SpA). 2016; ACR/ARHP Annual Meeting, Abstract-No: 2707
• 96 van der Heijde D, Lie E, Kvien TK. et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68: 1811-1818
• 97 Ramiro S, van der Heijde D, van Tubergen A. et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis 2014; 73: 1455-1461